Zymeworks Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026A merger combines two companies into one, changing ownership and potentially creating new growth opportunities.
Milestone payments give companies cash when drugs get approved, helping fund operations and research.
Quarterly reports show whether a company is making money and growing, helping investors track performance.
Companies announce earnings publicly so investors can see how well the business performed each quarter.
The CFO manages company money and finances, so this leadership change affects how the company handles its cash.
Selling future drug payment rights gives companies immediate cash but reduces future earnings.
Governance shows how a company is run and who oversees decisions, protecting shareholder interests.
Stocky reads Zymeworks Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Zymeworks Inc.'s most recent tracked filing was a 8-K on 29 Jun 2026: Zymeworks merging with Theravance in major deal.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.